Hahn Mark W 4
4 · SOLENO THERAPEUTICS INC · Filed May 18, 2026
Research Summary
AI-generated summary of this filing
Soleno (SLNO) Director Mark W. Hahn Receives $532,438 for 10,046 RSUs
What Happened
Mark W. Hahn, a director of Soleno Therapeutics, had 10,046 restricted stock units (RSUs) cancelled and converted into cash as part of the company’s May 18, 2026 merger. Each RSU was converted into $53.00 in cash, for total consideration of $532,438. The filing reports this as a disposition to the issuer (code D) rather than an open‑market sale.
Key Details
- Transaction date: 2026-05-18; price per share: $53.00; total cash received: $532,438. (10,046 × $53.00)
- Transaction type/code: Disposition to issuer (D) — cancellation/conversion of RSUs under the merger agreement.
- Shares owned after transaction: not specified in the filing.
- Footnote: Per the April 5, 2026 Agreement and Plan of Merger, each vested and unvested RSU was cancelled and converted into the right to receive $53.00 in cash as merger consideration.
- Filing timeliness: Reported on 2026-05-18 (same day as the transaction), so it appears timely.
Context
This was not an open‑market sale by the insider but a corporate action: the RSUs were converted into cash under the merger with Neocrine Biosciences (Merger Sub merged into Soleno, making Soleno a wholly owned subsidiary). Such conversions reflect deal terms rather than an individual trading decision and should be viewed as merger consideration, not a signal of personal bullish or bearish sentiment.
Insider Transaction Report
- Disposition to Issuer
Common Stock
[F1]2026-05-18−10,046→ 0 total
Footnotes (1)
- [F1]These shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration").